Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: Rare Oncogenic Alterations in NSCLC

New E-Learning module by Dr David Planchard is now available. Watch the presentation and take the CME test today!

ESMO members

Take the CME test and receive

1 ESMO - MORA point

119 slides / 1 hour 01 minutes

Learning objectives

  1. To describe rare oncogenic alterations occurring in patients with non-small cell lung cancer (NSCLC)
  2. To provide an update on clinical research in terms of targeting the rare oncogenic alterations and treatment resistance emerging in patients with NSCLC
  3. To put targeting of rare oncogenic alterations in NSCLC into precision oncology landscape

Description

In this E-Learning module, a world-renowned researcher in personalised treatments for non-small cell lung cancer (NSCLC) describes the frequency of targetable oncogenic driver molecular alterations, features rare oncogenic alterations, puts into clinical context targeting of BRAF, MET, HER2, ROS1, RET, NTRK, NRG1, and KRAS, and profoundly dissects the precision oncology landscape in patients with advanced NSCLC.

For each of the rare oncogenic alterations elaborated in this module, the author goes into detail about the pathway, targeted drugs available, the results from the clinical trials in terms of treatment outcomes and safety profile, the current place in the clinical practice guidelines and also tackles resistance.

In addition to describing the frequency of these molecular alterations, the author also describes the specificities in clinical presentation, provides the results from targeted therapies in clinical use, elaborates post-treatment resistance and provides an overview of ongoing clinical trials.

This module is an excellent example of recent achievements in precision oncology and illustrates the rapid transformation of a big cancer killer into many oncogene-driven subtypes.

In terms of diagnostic work-up, the author emphasizes the importance of a multidisciplinary discussion to determine optimal tissue procedure, biopsy, morphology, and the review of patients and tumour data. In terms of molecular profiling, the author highlights the role of integrated next-generation sequencing-based assay to detect mutations, amplifications and translocations. Furthermore, the author underlines patient selection and suitability for a plethora of recently developed targeted treatments

Last update: 22 Dec 2022

David Planchard has reported the following Financial Interests:
Advisory Board, Personal: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Samsung, Celgene, Abbvie, Daiichi Sankyo, Janssen.
Invited Speaker, Personal: AstraZeneca, Novartis, Pfizer, priME Oncology, Peer CME, Samsung, Abbvie, Janssen.
Non-Financial Interests:
Principal Investigator, Institutional financial interests: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Daiichi Sankyo, Sanofi-Aventis, Pierre Fabre.
Principal Investigator: Abbvie, Sanofi, Janssen.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.